Penumbra, Inc. (PEN)
Stock analysis · NYSE · Healthcare · Medical - Devices
Penumbra, Inc. (PEN) is a publicly traded company in the Healthcare sector. Latest price: $318.95. Market cap $12.56B. Trailing PE 79.94. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →You have viewed 4 SEO analysis pages
Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.
Continue with free signup1-Year Price
Earnings
Proprietary Signals
About Penumbra, Inc.
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD4…
Valuation
| P/E (TTM) | 79.94× |
|---|---|
| P/S (TTM) | 8.05× |
| P/B | 7.94× |
| P/FCF (TTM) | 62.72× |
| EV / EBITDA | 54.62× |
| EV / Sales | 8.02× |
| Earnings Yield | 1.25% |
| Free Cash Flow Yield | 1.59% |
Fundamentals
| Enterprise Value | $12.52B |
|---|---|
| Revenue (TTM) | $1.56B |
| Net Income (TTM) | $156.97M |
| Free Cash Flow (TTM) | $201.25M |
| Net Debt | -$44.89M |
| Working Capital | $1.14B |
| Gross Margin | 67.98% |
| Operating Margin | 12.13% |
| Net Margin | 10.06% |
| Return on Equity | 10.44% |
| Return on Invested Capital | 7.91% |
Peers
Recent News
- Penumbra, Inc. Reports Third Quarter 2026 Financial Results
- Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)
- Penumbra (NYSE:PEN) Stock Breaks Above 50-Day Moving Average – Should You Sell?
- New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technol…
- IART vs. PEN: Which Stock Is the Better Value Option?
Related
Browse more tickers: sitemap